These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35301150)

  • 1. Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds.
    Proj M; Knez D; Sosič I; Gobec S
    Drug Discov Today; 2022 Jun; 27(6):1733-1742. PubMed ID: 35301150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.
    Dahlin JL; Nissink JW; Strasser JM; Francis S; Higgins L; Zhou H; Zhang Z; Walters MA
    J Med Chem; 2015 Mar; 58(5):2091-113. PubMed ID: 25634295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput identification of promiscuous inhibitors from screening libraries with the use of a thiol-containing fluorescent probe.
    McCallum MM; Nandhikonda P; Temmer JJ; Eyermann C; Simeonov A; Jadhav A; Yasgar A; Maloney D; Arnold AL
    J Biomol Screen; 2013 Jul; 18(6):705-13. PubMed ID: 23446699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuisance Compounds, PAINS Filters, and Dark Chemical Matter in the GSK HTS Collection.
    Chakravorty SJ; Chan J; Greenwood MN; Popa-Burke I; Remlinger KS; Pickett SD; Green DVS; Fillmore MC; Dean TW; Luengo JI; Macarrón R
    SLAS Discov; 2018 Jul; 23(6):532-545. PubMed ID: 29699447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reference compounds for characterizing cellular injury in high-content cellular morphology assays.
    Dahlin JL; Hua BK; Zucconi BE; Nelson SD; Singh S; Carpenter AE; Shrimp JH; Lima-Fernandes E; Wawer MJ; Chung LPW; Agrawal A; O'Reilly M; Barsyte-Lovejoy D; Szewczyk M; Li F; Lak P; Cuellar M; Cole PA; Meier JL; Thomas T; Baell JB; Brown PJ; Walters MA; Clemons PA; Schreiber SL; Wagner BK
    Nat Commun; 2023 Mar; 14(1):1364. PubMed ID: 36914634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors.
    Dahlin JL; Nelson KM; Strasser JM; Barsyte-Lovejoy D; Szewczyk MM; Organ S; Cuellar M; Singh G; Shrimp JH; Nguyen N; Meier JL; Arrowsmith CH; Brown PJ; Baell JB; Walters MA
    Nat Commun; 2017 Nov; 8(1):1527. PubMed ID: 29142305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-stoichiometric inhibition in integrated lead finding - a literature review.
    Klumpp M
    Expert Opin Drug Discov; 2016; 11(2):149-62. PubMed ID: 26653534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuisance compounds in cellular assays.
    Dahlin JL; Auld DS; Rothenaigner I; Haney S; Sexton JZ; Nissink JWM; Walsh J; Lee JA; Strelow JM; Willard FS; Ferrins L; Baell JB; Walters MA; Hua BK; Hadian K; Wagner BK
    Cell Chem Biol; 2021 Mar; 28(3):356-370. PubMed ID: 33592188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens.
    Huth JR; Mendoza R; Olejniczak ET; Johnson RW; Cothron DA; Liu Y; Lerner CG; Chen J; Hajduk PJ
    J Am Chem Soc; 2005 Jan; 127(1):217-24. PubMed ID: 15631471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Frequently Are Pan-Assay Interference Compounds Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency, and Many Consistently Inactive Compounds.
    Jasial S; Hu Y; Bajorath J
    J Med Chem; 2017 May; 60(9):3879-3886. PubMed ID: 28421750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lies and Liabilities: Computational Assessment of High-Throughput Screening Hits to Identify Artifact Compounds.
    Alves VM; Yasgar A; Wellnitz J; Rai G; Rath M; Braga RC; Capuzzi SJ; Simeonov A; Muratov EN; Zakharov AV; Tropsha A
    J Med Chem; 2023 Sep; 66(18):12828-12839. PubMed ID: 37677128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-Sized Thiazoles in Fragment-Based Drug Discovery Campaigns: Friend or Foe?
    Proj M; Hrast M; Knez D; Bozovičar K; Grabrijan K; Meden A; Gobec S; Frlan R
    ACS Med Chem Lett; 2022 Dec; 13(12):1905-1910. PubMed ID: 36518695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments.
    Soares KM; Blackmon N; Shun TY; Shinde SN; Takyi HK; Wipf P; Lazo JS; Johnston PA
    Assay Drug Dev Technol; 2010 Apr; 8(2):152-74. PubMed ID: 20070233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening.
    Wigle TJ; Swinger KK; Campbell JE; Scholle MD; Sherrill J; Admirand EA; Boriack-Sjodin PA; Kuntz KW; Chesworth R; Moyer MP; Scott MP; Copeland RA
    J Biomol Screen; 2015 Jul; 20(6):810-20. PubMed ID: 25755264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoting GAINs (Give Attention to Limitations in Assays) over PAINs Alerts: no PAINS, more GAINs.
    Choo MZY; Chai CLL
    ChemMedChem; 2022 Apr; 17(7):e202100710. PubMed ID: 35146933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALARM NMR for HTS triage and chemical probe validation.
    Dahlin JL; Cuellar M; Singh G; Nelson KM; Strasser J; Rappe T; Xia Y; Veglia G; Walters MA
    Curr Protoc Chem Biol; 2018 Mar; 10(1):91-117. PubMed ID: 30034947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hit Dexter 2.0: Machine-Learning Models for the Prediction of Frequent Hitters.
    Stork C; Chen Y; Šícho M; Kirchmair J
    J Chem Inf Model; 2019 Mar; 59(3):1030-1043. PubMed ID: 30624935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Resazurin, Horseradish Peroxidase, and NMR Assays to Identify Redox-Related False-Positive Behavior in High-Throughput Screens.
    Tarnowski M; Barozet A; Johansson C; Eriksson PO; Engkvist O; Walsh J; Nissink JWM
    Assay Drug Dev Technol; 2018 Apr; 16(3):171-191. PubMed ID: 29608094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biophysics: for HTS hit validation, chemical lead optimization, and beyond.
    Genick CC; Wright SK
    Expert Opin Drug Discov; 2017 Sep; 12(9):897-907. PubMed ID: 28658992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using information from historical high-throughput screens to predict active compounds.
    Riniker S; Wang Y; Jenkins JL; Landrum GA
    J Chem Inf Model; 2014 Jul; 54(7):1880-91. PubMed ID: 24933016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.